MOBILE FRIENDY AGENDA

 

 

Barcelona, 10 - 12 October 2017

Schedule

Create your personal agenda –check the favourite icon

Oct 1008:50
Conference pass
Oct 1009:00
Conference pass

Opening plenary discussion: Creating a new strategy: How does the current global outbreak response system need to change?

Keynotes
Opening plenary discussion: Creating a new strategy: How does the current global outbreak response system need to change?
  • Efforts to develop an international fund to develop vaccines that are of low commercial interest but potentially epidemic-proof to the next emerging disease
  • Understanding the legal and regulatory framework for licensure of medical countermeasures during public health emergencies
  • How do we know which vaccines to stockpile? Initial efforts in MERS-CoV, Lassa and Nipah viruses
  • How should pharma and industry respond to developing low income vaccines?
  • What’s the global capacity and how fast can we develop a sustainable supply?
Oct 1010:00
Conference pass

Maternal immunisation: Where do we stand and how do we use vaccines, antivirals and antibodies – what’s the strategy?

Keynotes
  • Are we vaccinating the mums to protect the babies or to protect both
  • What are the challenges and unresolved questions around maternal immunization implementation
  • What are the vaccines in development and available today?
Oct 1010:30
Conference pass

Break the ice with your peers and exchange business cards in the conference room

Keynotes
Allowing conference delegates to meet each other for a short space of time and exchange business cards. A unique feature guaranteeing heightened networking for all participants
Oct 1011:40
Conference pass
Oct 1011:40
Conference pass

Chair’s opening remarks

Therapeutic Vaccines Track With Immune Profiling
Dr Emmett Schmidt, Exec Director, Clinical Research, Merck Research Laboratories - Oncology
Oct 1011:40
Conference pass

Chair’s opening remarks

ONE HEALTH with Veterinary Vaccines
Oct 1011:40
Conference pass

Chair’s opening remarks

Plenary
Oct 1011:45
Conference pass

Why haven't Alzheimer's vaccines succeeded yet?

Therapeutic Vaccines Track With Immune Profiling
 
  • Abeta and tau still valid AD targets
  • Past AD vaccines were very poorly immunogenic, explaining lack of efficacy
  • Structured AD vaccine design ensures maximal immune recognition
  • Good adjuvants are essential for effective AD vaccines
Oct 1011:45
Conference pass

Clinical development of a nasal inactivated influenza vaccine

Respiratory Vaccines Track
Oct 1011:45
Conference pass

Bringing together experts in human and animal health to create new platforms and technologies that will facilitate a fast, coordinated, and practical response to new infectious diseases

ONE HEALTH with Veterinary Vaccines
 
  • Targeting the animal reservoir
  • Commonalities and differences in approaches with human diseases
  • ZAPI-IMI efforts in combatting infectious diseases
Oct 1011:45
Conference pass

Why haven't Alzheimer's vaccines succeeded yet?

Plenary
 
  • Abeta and tau still valid AD targets
  • Past AD vaccines were very poorly immunogenic, explaining lack of efficacy
  • Structured AD vaccine design ensures maximal immune recognition
  • Good adjuvants are essential for effective AD vaccines
Oct 1011:45
Conference pass

Bringing together experts in human and animal health to create new platforms and technologies that will facilitate a fast, coordinated, and practical response to new infectious diseases as soon as the

Plenary
 
  • Targeting the animal reservoir
  • Commonalities and differences in approaches with human diseases
  • ZAPI-IMI efforts in combatting infectious diseases
Oct 1012:15
Conference pass

Delivering precision immunotherapy - Reprogramming dendritic cells to target patient specific antigens

Therapeutic Vaccines Track With Immune Profiling
Oct 1012:15
Conference pass

Progress and potential hurdles for development of a Universal flu vaccine

Respiratory Vaccines Track
Oct 1012:15
Conference pass

Delivering precision immunotherapy - Reprogramming dendritic cells to target patient specific antigens

Plenary

 
Oct 1012:45
Conference pass

Virus discovery – new kids on the block with pandemic potential

ONE HEALTH with Veterinary Vaccines
 
  • Comparing diseases side by side to “human diseases”
  • The importance of pathogen identification with unknown host transfer
Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover
Oct 1012:45
Conference pass

The challenge of childhood influenza vaccination in Europe

Respiratory Vaccines Track
 
  • Public Health importance, avenues of improvement and policies
Oct 1012:45
Conference pass

Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity

Therapeutic Vaccines Track With Immune Profiling
Oct 1012:45
Conference pass

Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity

Plenary
Dr Peter Timmerman, Chief Scientific Officer, Pepscan Therapeutics
Oct 1012:45
Conference pass

Virus discovery – new kids on the block with pandemic potential

Plenary
 
  • Comparing diseases side by side to “human diseases”
  • The importance of pathogen identification with unknown host transfer
Oct 1014:45
Conference pass

Assays used for vaccine efficacy studies and correlates of protection for influenza vaccines evaluation

Respiratory Vaccines Track
Oct 1014:45
Conference pass

Innovative mRNA vaccines – from proof of concept to product development, Rabies as an example

ONE HEALTH with Veterinary Vaccines
 
  • How can this global cooperative scientific reduces the risk of viral outbreaks over the next decade?
  • Challenges in doing so and hurdles needing to be overcome
  • Visionary thoughts for the future
Susanne Rauch, Senior Scientist, CureVac Gmbh
Oct 1014:45
Conference pass

The Global Virome Project: Bringing an end to pandemics

Plenary
 
  • How can this global cooperative scientific reduces the risk of viral outbreaks over the next decade?
  • Challenges in doing so and hurdles needing to be overcome
  • Visionary thoughts for the future
Oct 1014:45
Conference pass

A pan-HLA predictor of antigen processing and presentation to the cell surface improves the identification of clinically relevant neoantigens Bullet point summary:

Therapeutic Vaccines Track With Immune Profiling
  •     Current neoantigen discovery algorithms do not predict processing and presentation to the cell surface very well. 
  •     We outline a high-performing machine learning approach, trained on mass-spectrometry data, that predicts naturally processed and presented antigens.
  •     We illustrate its application to significantly improve identification of neoantigen targets for personalized cancer immunotherapy 
Oct 1014:45
Conference pass

A pan-HLA predictor of antigen processing and presentation to the cell surface improves the identification of clinically relevant neoantigens

Plenary
Oct 1015:00
Conference pass

Mucosal and Systemic Immune Responses to Influenza following Oral Tablet Delivery

Respiratory Vaccines Track
Comparisons between injected subunit vaccines and the tablet vaccine
Oct 1015:15
Conference pass

Using DNA vaccine based technology to prevent potentially life threatening allergies

Therapeutic Vaccines Track With Immune Profiling
Salim Mujais, Senior Vice President of Therapeutic Area Head, Immunology. Transplant, Infectious Disease, CNS & Pain, Astellas Pharma Inc
Oct 1015:15
Conference pass

Use of vaccination in animals for total epizootic disease eradication and anti-microbial resistance control

ONE HEALTH with Veterinary Vaccines
 
  • Using vaccination as an effective mean to treat bacterial animal infections at the source
  • Development of vaccines for decreasing use of antibiotics in terrestrial and aquatic animals
  • Using vaccination as a tool for total epizootic disease eradication (Dog Rabies, FMD and PPR)
  • Potential within the veterinary vaccine industry and challenges needing to be overcome
Oct 1015:15
Conference pass

Using DNA vaccine based technology to prevent potentially life threatening allergies

Plenary
Salim Mujais, Senior Vice President of Therapeutic Area Head, Immunology. Transplant, Infectious Disease, CNS & Pain, Astellas Pharma Inc
Oct 1015:15
Conference pass

Use of vaccination in animals for total epizootic disease eradication and anti-microbial resistance control

Plenary
- Using vaccination as an effective mean to treat bacterial animal infections at the source
- Development of vaccines for decreasing use of antibiotics in terrestrial and aquatic animals
- Using vaccination as a tool for total epizootic disease eradication (Dog Rabies, FMD and PPR)
- Potential within the veterinary vaccine industry and challenges needing to be overcome
 
Oct 1015:15
Conference pass

Prepare Trial: A Global, Multiseason, Phase 3 trial to evaluate the protective efficacy of the RSV F nanoparticle vaccine in infants using maternal immunization

Respiratory Vaccines Track
Oct 1015:45
Conference pass

Data supporting the value of check point inhibitors, AMPLIVANT SLP conjugates and neoantigens in combinational immunotherapy against HPV cancers

Therapeutic Vaccines Track With Immune Profiling
Oct 1015:45
Conference pass

Nanovaccines; A new platform technology for immunization against avian infections that impact human health

ONE HEALTH with Veterinary Vaccines
  • Utilizing avian influenza virus (AIV) proteins encapsulated within polyanhydride nanoparticles to develop a protective vaccine against outbreaks of high pathogenic and low pathogenic avian influenza
Oct 1015:45
Conference pass

Update on the development of the recombinant RSV vaccine candidate MVA-BN® RSV

Respiratory Vaccines Track
Oct 1015:45
Conference pass

Data supporting the value of check point inhibitors, AMPLIVANT SLP conjugates and neoantigens in combinational immunotherapy against HPV cancers

Plenary
Oct 1015:45
Conference pass

Nanovaccines; A new platform technology for immunization against avian infections that impact human health

Plenary
  • Utilizing avian influenza virus (AIV) proteins encapsulated within polyanhydride nanoparticles to develop
    a protective vaccine against outbreaks of high pathogenic and low pathogenic avian influenza
     
Oct 1016:45
Conference pass

The rationale of combining biomarkers and checkpoint inhibitors with vaccines and oncolytics

Therapeutic Vaccines Track With Immune Profiling
 
  • Use of biomarkers in cancer vaccine and combinational studies
Oct 1016:45
Conference pass

New insight and the challenges associated with the prevention and control of Rift Valley fever

ONE HEALTH with Veterinary Vaccines
 
  • New research and new data updates
  • The significant role of early detection, notification and information sharing during transboundary disease outbreak
  • Discussing the need to employ a “One Health” approach and update on recent efforts to control the recent outbreak of RVF in West Africa using the One Health approach
  • Reassessing the current vaccination strategy for RVF
Oct 1016:45
Conference pass

The rationale of combining biomarkers and checkpoint inhibitors with vaccines and oncolytics

Plenary
 
  • Use of biomarkers in cancer vaccine and combinational studies
Oct 1016:45
Conference pass

New insight and the challenges associated with the prevention and control of Rift Valley fever

Plenary
 
  • New research and new data updates
  • The significant role of early detection, notification and information sharing during transboundary disease outbreak
  • Discussing the need to employ a “One Health” approach and update on recent efforts to control the recent outbreak of RVF in West Africa using the One Health approach
  • Reassessing the current vaccination strategy for RVF
Oct 1016:45
Conference pass

Landscape analysis of RSV vaccine development and future implications

Respiratory Vaccines Track
Oct 1017:15
Conference pass

Developments and updates on an adjuvanted RSV F RSV Vaccine to protect healthy and high-risk older adults: building on clinical experience

Respiratory Vaccines Track
Oct 1017:15
Conference pass

Oncolytic viruses as immunotherapy - Establishing the legitimacy of oncolytic viruses in cancer therapy

Therapeutic Vaccines Track With Immune Profiling
 
  • Combinational potential with other immunotherapies
Oct 1017:15
Conference pass

Oncolytic viruses as immunotherapy - Establishing the legitimacy of oncolytic viruses in cancer therapy

Plenary
 
  • Combinational potential with other immunotherapies
Dr Brian Champion, CSO, Psioxus Therapeutics
Oct 1017:15
Conference pass

Development of proprietary polysaccharide vaccine adjuvants that meet the needs of humans and animals when concerning Influenza, West Nile and other re-emerged viruses

Plenary
 
  • Novel adjuvant combinations for veterinary and human vaccines
  • Production of vaccines in line with One Health considerations
  • Challenges faced, overcome and needing to be overcome for accelerated commercialisation and market access
Oct 1017:15
Conference pass

Development of proprietary polysaccharide vaccine adjuvants that meet the needs of humans and animals when concerning Influenza, West Nile and other re-emerged viruses

ONE HEALTH with Veterinary Vaccines
 
  • Novel adjuvant combinations for veterinary and human vaccines
  • Production of vaccines in line with One Health considerations
  • Challenges faced, overcome and needing to be overcome for accelerated commercialisation and market access

Create your personal agenda –check the favourite icon

Oct 1109:00
Conference pass

Chair’s opening remarks

Plenary
Oct 1109:10
Conference pass

Plenary discussion: Where is the global vaccine industry shifting to for new collaborations? Perspectives from emerging markets and Asia

Keynotes
 
  • The role of emerging markets in the global supply and demand for vaccines
  • What vaccine technologies and vaccine candidates are favourable?
  • Does it align with other philanthropy organisations?
  • The role of Public-Public Partnerships (P2Ps) in vaccine R&D for poverty related and neglected diseases (PRNDs)
  • Priorities for linking new vaccine development with public health in low and middle income countries
Oct 1109:10
Conference pass

Development of TCR based adoptive T cell therapies: opportunities and challenge

Plenary
  • Discovery and Development of T-cells for immunotherapies
  • Identifying patient populations and expanding the responding population
  • TCR targeting of neoantigens
  • Addressing potential challenges in cell based immunotherapies
Oct 1109:10
Conference pass

Prevention of food borne diseases through vaccination: challenges and opportunities in the global poultry industry

Plenary
 
  • Economic impact of Foodborne diseases to the Global Poultry Industry
  • Emerging/re-emerging foodborne disease pathogens impacting the Global Poultry Industry  
  • Prevention of Food borne zoonosis through vaccination of Poultry: Challenges and opportunities
Oct 1109:40
Conference pass

Disease prevention in relation to animal welfare

Plenary
 
  • The importance of risk control, identifying current and predicted risks and addressing how these can be minimised effectively
  • Discussing the industries role when concerning risk control and assessing how the industry can address the current risk control issue
Oct 1109:40
Conference pass

Combinational immunotherapy in oncology: increasing the effective targeting of neo-epitopes

Plenary
 
  • PD-1 Antibodies have the potential to be a broad spectrum antineoplastic treatment both as monotherapy and in combination therapies
  • Discussing the efficacy and toxicity profiles of therapeutic combinations
  • Current opportunities, challenges and the potential for unforeseen side effects
  • Thoughts for the future for combination immunotherapy in oncology
Oct 1110:10
Conference pass

Where are we in polio eradication? What are the remaining challenges?

Keynotes
  • How we will maintain a polio-free world
  • Are new/different vaccines required in the post eradication era?
Oct 1110:10
Conference pass

Development of a Serum Free Medium for Expansion of BHK-21 Cells for Vaccine Production

Plenary
Cell culture media is a critical driver in the biopharmaceutical production process and peptones are frequently used to enhance performance of production media. BHK-21 is an industrially relevant cell line used for production of various animal health vaccines, such as foot-and-mouth disease and rabies. These cells are typically grown in cell culture media supplemented with serum, which introduces additional costs and variability into the process. Understanding the requirements of the animal-health vaccine market, we have leveraged our expertise in peptones and cell culture media development, to develop a high performance serum-free medium for the expansion of BHK-21 cells for vaccine production
Oct 1110:10
Conference pass

Integrated Immune Monitoring Solutions for Preclinical and Clinical Development of Immunotherapeutics

Plenary
  • Multicolor-cytometry to accelerate preclinical and clinical development of checkpoints inhibitors
  • Immune profiling of vaccines
  • Fit-for-purpose assays: Integration of scientific expertise and high-end technology in a quality system
Oct 1111:40
Conference pass

Interactive Roundtables

Keynotes
Choose which two roundtable discussions you would like to join, for ‘off the beaten track’ learning and information you can’t find online. Each session will last 45 minutes so you can join two discussions in the allotted time. The same roundtables will be run twice back to back.

Incorporating “passive immunization” with vaccines – the use of Phage therapies and mABs
Dr Eszter Nagy, Co-Founder, Chief Scientific Officer, and Managing Director, Arsanis Biosciences GmbH

The significant role of the microbiome in disease prevention, treatment and therapeutic development
Jeff Riley, CEO, Synthetic Biologics, Inc.

The regulators relationship with Challenge Studies; yesterday, today and tomorrow
Bruno Speder, Head Clinical Regulatory Affairs, SGS Life Sciences
Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences

 Advanced veterinary therapies: stem cells, monoclonal antibodies and bacterial phages for veterinary use     
Dr Rosario Bullido, Head of Veterinary Inmunological Medicines Assessment Unit, AEMPS

Intradermal delivery of therapeutic vaccines – benefits and challenges
Dr Kirsty V Gapp, Global Business Manager Transdermal and Microneedle Drug Delivery, 3M 

Porcine T lymphocytes – analysis of their response after vaccination
Prof Dr Armin Saalmüller, Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna

Using an autologous cancer vaccine to enhance immunotherapy outcomes and tackle a re-occurring disease within companion animals
Dr Patrick Frayssinet, R&D Director

Developing vaccines to emerging diseases and effective use of animal models

Professor Miles W Carroll, Head of Research, Deputy Director, National Infections Service, Public Health England

Trends in mammalian cell culture based vaccines
Ron Geven, BD Biosciences
Dr James W. Brooks, R&D Manager, BD Biosciences

Progress on Zika vaccine development
Dr Gregory Poland, Director, Mayo Clinic
 
Sponsor/CRO Partnership Optimization
Marc Hoffman, CMO, Celerion
Bernhard Liegl, VP Global Clinical Development, Celerion
Susanne Eder-Lingelbach, Head of Clinical Operations, Valneva
Oct 1111:40
Conference pass

Interactive Roundtables

Plenary
Choose which two roundtable discussions you would like to join, for ‘off the beaten track’ learning and information you can’t find online. Each session will last 45 minutes so you can join two discussions in the allotted time. The same roundtables will be run twice back to back.

Incorporating “passive immunization” with vaccines – the use of Phage therapies and mABs
Dr Eszter Nagy, Co-Founder, Chief Scientific Officer, and Managing Director, Arsanis Biosciences GmbH

The significant role of the microbiome in disease prevention, treatment and therapeutic development
Jeff Riley, CEO, Synthetic Biologics, Inc.

The regulators relationship with Challenge Studies; yesterday, today and tomorrow
Bruno Speder, Head Clinical Regulatory Affairs, SGS Life Sciences
Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences

Advanced veterinary therapies: stem cells, monoclonal antibodies and bacterial phages for veterinary use     
Dr Rosario Bullido, Head of Veterinary Inmunological Medicines Assessment Unit, AEMPS

Vaccine delivery: How to increase efficacy of vaccines, and the challenges from moving to therapeutic vaccines versus prophylactic
Kristy Gapp, 3M

Porcine T lymphocytes – analysis of their response after vaccination
Prof Dr Armin Saalmüller, Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna

Using an autologous cancer vaccine to enhance immunotherapy outcomes and tackle a re-occurring disease within companion animals
Dr Patrick Frayssinet, R&D Director

Developing vaccines to emerging diseases and effective use of animal models

Professor Miles W Carroll, Head of Research, Deputy Director, National Infections Service, Public Health England

Trends in mammalian cell culture based vaccines
Ron Geven, BD Biosciences
Dr James W. Brooks, R&D Manager, BD Biosciences

Progress on Zika vaccine development
Dr Gregory Poland, Director, Mayo Clinic


Sponsor/CRO Partnership Optimization
Marc Hoffman, CMO, Celerion
Bernhard Liegl, VP Global Clinical Development, Celerion
Susanne Eder-Lingelbach, Head of Clinical Operations, Valneva
Oct 1111:40
Conference pass

Advanced development of innovative immunotherapeutics: in combination and exploiting the DART platform

Plenary
 
  • Overview of current progress, lessons learned, and future prospects for the combination immunotherapy of cancer
  • Discussing how application of the DART platform leads to enhanced checkpoint blockade
  • Mechanisms by which anti-tumour immune responses can be evoked when employing the novel DART platform
Oct 1112:10
Conference pass

High-resolution profiling of antibody responses to arrays of peptides

Plenary
 
  • Applications in vaccines, oncology, autoimmune disorders, antibody discovery
Oct 1112:25
Conference pass

High-throughput sequencing for the T Cell and B Cell repertoire profiling

Plenary
 
  • Effectively employing high-throughput sequencing for advanced profiling
  • Exploiting computational tools for the profiling of T-cell and B-cells for therapeutic developments
Oct 1112:40
Conference pass

Development of active immune therapies and therapeutic vaccination strategies for haematological malignancies

Plenary
Prof Farzin Farzaneh, Professor of Molecular Medicine, King's College Hospital NHS Trust
Oct 1114:40
Conference pass

Chair’s opening remarks

Early Development & Manufacturing
Oct 1114:40
Conference pass

Chair’s opening remarks

Clinical Development in Viral Vaccines
Oct 1114:40
Conference pass

Manufacturing within the veterinary industry – the future of where it’s going

Plenary
  • The significance of manufacturing quality control for veterinary vaccine development and vaccine efficacy
  •  New manufacturing technologies to that could potentially be commercially viable, and enable effective and rapid response during outbreaks 
  • Challenges the veterinary vaccine manufacturing is currently facing and steps to overcome these
Oct 1114:40
Conference pass

Improving the anti-tumor immune response through the use of bi-and trifunctional antibody-cytokine fusion proteins

Plenary
 
  • Designing bi- and trifunctional antibody-fusion proteins with IL-15 and costimulatory members of the B7 and TNF superfamily
  • Sharing research which shows enhanced immune responsiveness in vitro and anti-tumour activity in a mouse model in vivo
  • Discussing mode of action employed
Oct 1114:45
Conference pass

Development of live measles vaccine vector for new emerging pathogens

Emerging & Re-emerging Diseases
  • Developing attenuated measles Schwarz vaccine virus into a versatile chimeric or recombinant vector
  • Proof of concept in humans
  • The potential of measles vector as a platform for rapid response to new pathogens
Oct 1114:45
Conference pass

Pre- formulation and stability studies in different vaccines – key considerations

Early Development & Manufacturing
Oct 1114:45
Conference pass

The challenges of clinical development for emerging infectious diseases – The Example of Ebola

Clinical Development in Viral Vaccines
Oct 1115:10
Conference pass

Prioritising diseases for which vaccines could reduce antimicrobial use in animals

Plenary
  • Preserving the effectiveness of antibiotics
  • Highlighting the gaps in research and development for vaccine preventable diseases in poultry, swine and fish
  • Preventing further consequences of secondary infections
  • Sharing GMP and quality standards for poultry and swine vaccines and diagnostics
Oct 1115:10
Conference pass

Accuracy and prediction in antibody repertoire analysis 

Plenary
 
  • Novel error and bias correction of antibody repertoire data
  • Combining repertoire analysis with machine learning methods for predicting antigen exposure and specificity 
  • Functional screening of antibody repertoires using mammalian surface display technology
Oct 1115:15
Conference pass

Strain and species-specific antibody response in a malaria vaccine field trial and after flavivirus infection

Emerging & Re-emerging Diseases
Oct 1115:15
Conference pass

How Innovative Process Development Allows for a Novel Cost-effective Rotavirus Vaccine

Early Development & Manufacturing
The development of novel technologies within biotechnology is highly dynamic, but implementation of these innovations into a manufacturing process stays behind. Three novel technologies are linked to create a simple, but robust, automated vaccine manufacturing platform that can deliver high yields at low cost. The technology platform links mammalian cell lines used for vaccine production in a compact, high cell density bioreactor, and affinity purification into a cost effective automated vaccine manufacturing system in a self-contained miniaturized facility. Polio vaccine production will be used to showcase the new miniaturized production system.
 
Oct 1115:15
Conference pass

The problem with powering…PhII to PhIII, quo vadis?

Clinical Development in Viral Vaccines
Identifying contributing factors to late phase failure and to provide some insights into models for future Phase II trials to better evidence efficacy in the field
Oct 1115:30
Conference pass

Innovative affinity chromatography platform for streamlined purification of vaccines at reduced costs and lower environmental footprint

Early Development & Manufacturing
DiViNe Project
Anne Chevrel, Research and Development Project Manager, Affilogic
Oct 1116:15
Conference pass

Bioengineering bacterial outer membrane vesicles as vaccine platform

Early Development & Manufacturing
Oct 1116:15
Conference pass

The role of omics in veterinary vaccinology: opportunities and challenges 

Plenary
 
  • How can we exploit omics technology to advance veterinary innovation? 
  • Transcriptomics provide markers for potent adjuvants and vaccine efficacy  
  • Transcriptomics help to identify immunological processes crucial for vaccine-induced immunity 
Oct 1116:15
Conference pass

Adjuvant profiling and systems analysis of vaccine induced response to enhance correlates of protection of human vaccines

Plenary
 
  • Learn opportunities offered by systems analysis of response to human vaccines and adjuvants to inform rational vaccine development
  • Discussing the significance of new biomarkers in vaccine development
  • Sharing ongoing efforts within EU financed research programmes
Oct 1116:15
Conference pass

Use of MAV-VLP platform for development of vaccines for infectious diseases and cancer

Clinical Development in Viral Vaccines

 
Oct 1116:15
Conference pass

Developing a universal vaccine  against emerging mosquito-transmitted diseases and influenza

Emerging & Re-emerging Diseases
 
  • Clinical update and approach taken
  • Scientific analysis and trial design
  • Feedback on fast track development and regulatory programmes
  • Next steps and applications
Oct 1116:30
Conference pass

MACIVIVA – Developing cold chain independent virosomal vaccines

Early Development & Manufacturing
Oct 1116:45
Conference pass

Challenges of RSV vaccine development

Early Development & Manufacturing
Oct 1116:45
Conference pass

African Swine Fever –  dealing with what is yet to come

Plenary
 
  • Addressing epidemiology and the increasing risk of its spread across Europe
  • Developing vaccines to address ASF – where do we stand?
  • Challenges needing to be overcome
Oct 1116:45
Conference pass

Oncolytic Virotherapy: A New Cornerstone for Immuno-Oncology

Plenary
  • Using engineered viruses to help cure cancer
  • Testing combinations in various clinical stages to harness and enhance the body’s natural tumour-killing immune responses
Oct 1116:45
Conference pass

From vaccines research to launch of Dengvaxia and collaborative efforts to create a Zika vaccine

Emerging & Re-emerging Diseases
  • The Dengvaxia research to launch journey: Lessons learned
  • Implications for the future of dengue control
  • Flavivirus Epidemics Preparedness : Developing a Zika vaccine – current status
Oct 1116:45
Conference pass

ViroSpot MN assay, a novel tool for antigenic characterization of influenza viruses and serology

Clinical Development in Viral Vaccines
- Virospot Assay platform and principles
- Application: RSV Virospot neutralization
- WHO Micro Neutralization and Virospot Micro Neutralization Assay
Oct 1117:15
Conference pass

Preventing the pandemic potential of MERS-CoV: Updates on research and clinical development

Emerging & Re-emerging Diseases

 
Oct 1117:15
Conference pass

Standardization and development of assays for assessment of influenza vaccines correlates of protection

Clinical Development in Viral Vaccines

Create your personal agenda –check the favourite icon

Oct 1209:00
Conference pass

Chair’s opening remarks

Bacterial Vaccines & Anti-Microbial Resistance
Oct 1209:00
Conference pass

Chair’s opening remarks

Technology Supporting Delivery & Manufacture
Oct 1209:00
Conference pass
Oct 1209:10
Conference pass

Technology Showcase 1: Proprietary VLP technology for developing safe and efficacious vaccines against enteroviruses and HFMD

New Technology & Discovery

 
Oct 1209:10
Conference pass

The role of vaccines to combat antibiotic-resistant bacteria – WHO perspective

Bacterial Vaccines & Anti-Microbial Resistance
Oct 1209:10
Conference pass

Manufacturing capacity planning for Live Virus Vaccines and its impact on product development priorities

Technology Supporting Delivery & Manufacture
Oct 1209:10
Conference pass

Developing veterinary vaccines for emerging and re-emerging diseases: gaps and requirements

Plenary
 
  • Key considerations when launching a veterinary vaccine development programme
  • Highlighting the constraints that are enforced by national and European regulatory authorities and provide obstacles to obtaining market authorisation
  • Promising areas of development
Oct 1209:10
Conference pass

Application of sequential vaccination for educated immune responses

Plenary
  • Employing single cell transcriptomics and advanced X-50 ow cytometry technologies to detect immune response within HIV positive and negative patients 
  • Highlighting the wider potential for single cell transcriptomics and X-50 technology within the vaccination field 
Oct 1209:25
Conference pass

Technology Showcase 2 : Development of a novel vaccine for Zika that does not bear the inherent risk of inducing ADE

New Technology & Discovery
Oct 1209:40
Conference pass

Technology Showcase 3 : Using mAbs for targeted immunotherapy against bacterial infections

New Technology & Discovery
Oct 1209:40
Conference pass

VPM1002: A recombinant BCG as a novel infant and post-exposure adult tuberuclosis vaccine

Bacterial Vaccines & Anti-Microbial Resistance
Oct 1209:40
Conference pass

Virus safety for viral vaccines and viral vectors

Technology Supporting Delivery & Manufacture
Oct 1209:40
Conference pass

A transboundary problem: Lumpy Skin Disease (LSD)

Plenary

  • Reviewing the current spread of the disease and the role of the vectors and the environmental factors in the epidemiology of the disease
  • Addressing the vital issue of vaccination against lumpy skin disease. Is vaccination the most effective control method?
  • How can Europe effectively deal with this re-emerging challenge?
Oct 1209:40
Conference pass

Immune profiling of anti-drug antibodies

Plenary
Oct 1209:55
Conference pass

Technology Showcase 4 : Structure-based design to tackle vaccine challenges

New Technology & Discovery
Oct 1210:10
Conference pass

Prevention of relapse after Abx treatment

Bacterial Vaccines & Anti-Microbial Resistance
Oct 1210:10
Conference pass

Viral vectors as vaccine platforms: From immunogenicity to impact

Technology Supporting Delivery & Manufacture
Oct 1210:10
Conference pass

Technology Showcase 5 : The next generation of conjugate vaccine against Streptococcus pneumoniae infection: A novel bioconjugation approach

New Technology & Discovery
Oct 1210:10
Conference pass

Peste des Petits Ruminants: state of affairs and the road towards eradication

Plenary
  • Review of our knowledge of PPR epidemiology and the threat of this disease to Europe
  • Recent and on-going research of major importance for the success of the eradication, notably on vaccine development
  • Major gaps in our knowledge of this disease and how those could hinder the global eradication effort
Oct 1210:10
Conference pass

Developing effective biomarker strategies for advanced clinical development of Immune mobilising monoclonal TCRs against cancer (ImmTACs)

Plenary
 
  • Sharing updates on the phase I/IIa clinical trials in advanced melanoma
  • Employing a unique biomarker strategy which allows for comprehensive analysis of markers within the tumour as well as the surroundings
  • Enhanced knowledge acquired regarding the biologic mechanisms and response rates
Oct 1210:25
Conference pass

Technology Showcase 6 : Novel eVLP Candidates to Prevent Leading Causes of Congenital Birth Defects

New Technology & Discovery
Oct 1211:20
Conference pass
Oct 1211:20
Conference pass

Technology Showcase 7 : Producing affordable vaccines with high productivity manufacturing technologies

New Technology & Discovery
Oct 1211:20
Conference pass

Extraintestinal pathogenic E. coli: Challenges for vaccine development and clinical progress

Bacterial Vaccines & Anti-Microbial Resistance
Oct 1211:20
Conference pass

Application of DIVA vaccines to address Bovine Tuberculosis in Cattle

Plenary
 
  • Discussing progress made on optimizing the only potentially available vaccine, bacille Calmette Guérin (BCG)
  • What strategies are there to improve BCG efficacy?
  • Highlighting recent advances in DIVA development based on the detection of host cellular immune responses by blood-testing or skin-testing approaches
  • What are the next steps necessary in order to accelerate DIVA vaccine development?
Oct 1211:20
Conference pass

Harnessing natural bacterial products to develop pioneering and gentle immunotherapy treatments

Plenary
  • The potential to develop drugs from bugs
  • The Old Friend’s hypothesis: implications for the field of immunotherapy
  • Overview of current clinical and pre-clinical development programmes
  • Highlighting immune-modulatory mode of mechanism
Oct 1211:40
Conference pass

Clinical update on the Staphylococcus aureus multi-antigen vaccine

Bacterial Vaccines & Anti-Microbial Resistance
Oct 1211:40
Conference pass

Overview of the challenges and opportunities presented by plant-based vaccine manufacturing

Technology Supporting Delivery & Manufacture
Oct 1211:40
Conference pass

Technology Showcase 8 : Displaying antigens on Virus-Like-Particles using the plug-and-display SpyCatcher/SpyTag technology

New Technology & Discovery
Oct 1211:50
Conference pass

The Global Virome Project: Bringing an end to pandemics

Plenary
 
  • Sharing progressive updates on the rapid response to quickly produce several effective vaccines
  • Challenges faced, steps taken to overcome these and thoughts for future emerging disease outbreaks.  
Oct 1211:50
Conference pass

ABX196, a promising iNKT agonist to enhance therapeutic efficacy in oncology

Plenary

 
Oct 1212:00
Conference pass

The threat GAS as AMR rises and the promise of a vaccine

Bacterial Vaccines & Anti-Microbial Resistance
Oct 1212:00
Conference pass

Technology Showcase 9: From Chikungunya to Zika and other emerging diseases: rapid development based on vector platform

New Technology & Discovery
Oct 1213:20
Conference pass
Oct 1213:20
Conference pass

The quest to develop new and improved vaccines for a range of economically important livestock diseases

Plenary
 
  • Research and data updates in line with Moredun’s veterinary vaccine research
  • Sharing information on development portfolio for vaccines for a range of endemic diseases, particularly parasitic diseases
  • Case study: Barbervax, a vaccine against Haemonchus gastrointestinal worms in sheep 
Oct 1213:20
Conference pass

Engineering 2nd Generation SPEAR™-T cells to Overcome TGF-β-Mediated Immunosuppression

Plenary
 
  • NY-ESO SPEAR-T cells show promise in clinical trials for solid and liquid tumours
  • Depth and durability of responses may be affected by inhibitory cytokines such as Transforming Growth Factor-β (TGF-β) in the tumour microenvironment
  • Preclinical assessment of a dominant negative TGF-β receptor (dnTGFβRII) to make T cells resistant to the inhibitory effects of TGF-β
Oct 1213:30
Conference pass

Vaccines against antibiotic resistance: The PCV paradigm

Keynotes
 
  • Using PCVs to reduce antibiotic resistance by reducing the vaccine serotype distribution
  • The significance of reducing antibiotic use in children and consequently rest of the population
  • What needs to be done with the appropriate education of reduced antibiotic abuse
Oct 1213:50
Conference pass

Fast track licensing: rapid registration of novel vaccine platforms panel

Plenary
 
  • Industry and regulatory perspectives
  • Addressing acceleration of the licensing and registration process for new vet tech
  • Hear from a company who has successfully registered a novel vaccine platform through fast track licensing.
  • Discussing current challenges, hurdles faced, challenges overcome and thoughts for future
Additional panellists to be confirmed shortly..
Dr Rosario Bullido, Head of Veterinary Inmunological Medicines Assessment Unit Veterinary Medicines Department, Aemps
Phillipe Migraine, Director Regulatory Affairs, Merial
Oct 1213:50
Conference pass

Targeting cancer neoantigens: a promising source of immunogens for cancer immunotherapy

Plenary
 
  • Employing novel antibodies against immunogenic neoantigens
  • Antibody development using a novel platform exploiting immunogenic human tumor antigens
  • How to identify tumor specific monoclonal antibodies with anti-tumor activity and target antigens
  • Sharing pre-clinical and PhII clinical data in patients  
Oct 1214:05
Conference pass

The intestinal microbiome and vaccine effectiveness: Correlation or causality

Keynotes
 
  • Understand the Microbiome and its interaction with the immune system
  • How to effectively manipulate the microbiome to improve vaccine efficacy
  • Potential opportunities and current challenges
Oct 1214:20
Conference pass

Enabling boosted anti-tumor immunity by use of an immuno-oncology-dedicated adenosine receptor antagonist

Plenary
 
  • Sharing data updates
  • Characterization of a novel Adenosine A2A Receptor antagonist optimized to function in high adenosine concentrations within tumors
  • Defining the receptors essential for mediation of the effect of adenosine on immune cells within the tumor microenvionment
  • Translational strategy to improve the antitumor efficacy in patients
Oct 1214:50
Conference pass

Increasing availability of veterinary medicinal products through harmonisation of national regulation regarding autogeneous farm specific vaccines

Plenary
 
  • The need to harmonise requirements and the understanding of “in the same locality”, regarding the concept of epidemiological links between farms
  • Discussing the importance of defining good practices regarding the manufacture and control of autogenous vaccines
  • Considering potential implementation strategies to incorporate harmonisation within legislative framework
Oct 1214:50
Conference pass

  Immunoprofiling of tumour-draining lymph nodes: new targets for early intervention

Plenary
 
  • Immunoprofiling of lymph nodes draining various tumor types has uncovered different immune suppressive mechanisms at play  
  • Different combinations of locally applied TLR-ligands and/or immune checkpoint inhibitors should be considered for therapeutic conditioning of lymph nodes draining different tumor types.
  • Immune suppression of migratory and resident DC subsets in melanoma sentinel lymph nodes is differentially related to locoregional and distant metastasis.
  • Local immune modulation of melanoma-draining lymph nodes by CpG or anti-CTLA4 leads to systemic T cell immunity and protection against metastatic spread.
Oct 1214:55
Conference pass

Plenary Discussion: Vaccines don’t protect, vaccination does

Keynotes
 
  • How much damage is done with the wrong information?
  • The use of vaccines or the failure to do so
  • Why make new vaccines if we have old ones that work but aren’t being used?
  • Paving the way for a framework capable of rapidly delivering reliable data on the benefits and risks of vaccines that are on the market

More panellists to be confirmed
Oct 1215:20
Conference pass

Harmonisation of registration requirements for veterinary vaccines in East Africa and a regional, time-based Mutual Recognition Procedure

Plenary
 
  • Harmonising technical requirements
  • Development of a Mutual Recognition Procedure (MRP)
  • Implementing MRP in the East African Community
last published: 05/Oct/17 16:46 GMT